International Journal of Cancer

Cover image for Vol. 139 Issue 3

Early View (Online Version of Record published before inclusion in an issue)

Editor-in-Chief: Professor Peter Lichter, DKFZ, Germany

Impact Factor: 5.085

ISI Journal Citation Reports © Ranking: 2014: 31/211 (Oncology)

Online ISSN: 1097-0215


  1. 1 - 57
  1. Cancer Epidemiology

    1. Association between selected dietary scores and the risk of urothelial cell carcinoma: A prospective cohort study

      Pierre-Antoine Dugué, Allison M. Hodge, Maree T. Brinkman, Julie K. Bassett, Nitin Shivappa, James R. Hebert, John L. Hopper, Dallas R. English, Roger L. Milne and Graham G. Giles

      Version of Record online: 19 MAY 2016 | DOI: 10.1002/ijc.30175

      What's new?

      When components of the food we eat interact with the lining of the urethra on their way out, they can influence urothelial cell carcinoma. Various studies have tried to quantify the impact of individual nutrients on UCC risk; this study instead focused on the diet as a whole. Each person's dietary pattern received a score on three separate scales that reflect different philosophies of healthy eating, but the scores did not correlate with overall urothelial cell cancer risk. The authors did find that people with a healthier diet had a lower risk of invasive cancers, and healthier eating especially benefitted smokers.

    2. You have full text access to this OnlineOpen article
      Record linkage to correct under-ascertainment of cancers in HIV cohorts: The Sinikithemba HIV clinic linkage project

      Mazvita Sengayi, Adrian Spoerri, Matthias Egger, Danuta Kielkowski, Tamaryn Crankshaw, Christie Cloete, Janet Giddy and Julia Bohlius

      Version of Record online: 18 MAY 2016 | DOI: 10.1002/ijc.30154

      What's new?

      The surveillance of HIV-related cancers is hampered by the lack of systematic collection of cancer diagnoses in HIV cohorts and the absence of HIV status in cancer registries. While probabilistic record linkage has been widely used in Europe and America, it has not been fully exploited in resource-limited settings. This study demonstrates the utility of record linkage in correcting under-ascertainment of cancers in HIV cohorts and a high cancer incidence among HIV-positive patients on antiretroviral therapy in South Africa. There is a need for a systematic approach to cancer surveillance in HIV-positive people in the South African antiretroviral therapy era.

    3. Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: A historical cohort study

      Geoffrey Buckle, Louise Maranda, Jodi Skiles, John Michael Ong'echa, Joslyn Foley, Mara Epstein, Terry A. Vik, Andrew Schroeder, Jennifer Lemberger, Alan Rosmarin, Scot C. Remick, Jeffrey A. Bailey, John Vulule, Juliana A. Otieno and Ann M. Moormann

      Version of Record online: 18 MAY 2016 | DOI: 10.1002/ijc.30170

      What's new?

      Endemic Burkitt lymphoma (eBL) is the most common pediatric cancer diagnosed in Equatorial Africa. However, while B-cell lymphomas have the potential for complete remission, estimated survival rates for eBL patients in Africa are low, likely owing to unique regional factors. The present study shows that malaria, anemia and high-dose cyclophosphamide contribute to poor outcomes for African children diagnosed with eBL. Importantly, peripheral blood titers of Epstein-Barr virus, an eBL risk factor, were not associated with patient outcome. The findings provide a basis for the future evaluation of strategies to improve eBL treatment and survival.

  2. Tumor Immunology and Microenvironment

    1. Interaction of acid ceramidase inhibitor LCL521 with tumor response to photodynamic therapy and photodynamic therapy-generated vaccine

      Mladen Korbelik, Judit Banáth, Wei Zhang, Kyi Min Saw, Zdzislaw M. Szulc, Alicja Bielawska and Duska Separovic

      Version of Record online: 18 MAY 2016 | DOI: 10.1002/ijc.30171

      What's new?

      Acid ceramidase, one of the key enzymes in sphingolipid metabolism, has been identified as a promising target for cancer therapy. Using a head and neck cancer mouse model, here the authors examine the effectiveness of acid ceramidase inhibitor LCL521 as adjuvant to photodynamic therapy (PDT). They show that targeting acid ceramidase can be successfully exploited in combined treatments with PDT or PDT-generated vaccines. LCL521 treatment enhances direct lethal effects initiated by PDT-induced oxidative stress responses in vitro. In vivo, the hindering effects of major immunoregulatory populations following PDT of tumors or related vaccine protocols can be restrained by LCL521 treatment.

  3. Cancer Epidemiology

    1. Physical activity from menarche to first pregnancy and risk of breast cancer

      Ying Liu, Deirdre K. Tobias, Kathleen M. Sturgeon, Bernard Rosner, Vasanti Malik, Elizabeth Cespedes, Amit D. Joshi, A. Heather Eliassen and Graham A. Colditz

      Version of Record online: 17 MAY 2016 | DOI: 10.1002/ijc.30167

      What's new?

      Physical activity is associated with lower breast cancer risk, but the periods of life offering most protective benefits remain unclear. With a longer interval between menarche and first pregnancy known to be associated with elevated breast cancer risk, here the authors set to examine the influence of physical activity between the two reproductive events. Physical activity was associated with a lower risk of breast cancer among women with at least 20 years between menarche and first pregnancy. Physical activity may thus offer women an option to mitigate breast cancer risk associated with a longer interval between menarche and first pregnancy.

  4. Tumor Immunology and Microenvironment

    1. Growing tumors induce a local STING dependent Type I IFN response in dendritic cells

      Lisa Andzinski, Julia Spanier, Nadine Kasnitz, Andrea Kröger, Lei Jin, Melanie M. Brinkmann, Ulrich Kalinke, Siegfried Weiss, Jadwiga Jablonska and Stefan Lienenklaus

      Version of Record online: 17 MAY 2016 | DOI: 10.1002/ijc.30159

      What's new?

      Type I interferons (IFNs) are crucial for cancer immune surveillance. However, the source of these molecules during tumor growth has not been well understood. In this study, the authors used an in vivo reporter system to visualize IFN-β expression. They found that STING and the downstream transcription factors IRF3 and IRF5 are crucial for IFN-β induction, that tumor-infiltrating dendritic cells (DCs) and tumor cells themselves are major sources of IFN-b, and that tumor-derived DNA may act as a trigger for this induction. These results suggest novel therapeutic targets.

  5. Infectious Causes of Cancer

    1. Invasive Fusobacterium nucleatum may play a role in the carcinogenesis of proximal colon cancer through the serrated neoplasia pathway

      Jiahui Yu, Yongyu Chen, Xiangsheng Fu, Xian Zhou, Yan Peng, Lei Shi, Ting Chen and Yaxin Wu

      Version of Record online: 17 MAY 2016 | DOI: 10.1002/ijc.30168

      What's new?

      A member of the oral microbiome, Fusobacterium nucleatum (Fn) is an opportunistic pathogen beyond the oral cavity. Notably, it is overabundant in colorectal tumors, where its presence frequently is associated with CpG island methylator phenotype-high lesions, which typically occur in the proximal colon. The present study suggests that invasive Fn is involved primarily in the carcinogenesis of proximal colon cancers that develop along the serrated neoplasia pathway, having only a minor role in the traditional adenoma-carcinoma sequence. The findings provide a basis for the investigation of novel tools for Fn detection and patient stratification in colorectal cancer.

  6. Mini Reviews

    1. Tumour angiogenesis—Origin of blood vessels

      S. Krishna Priya, R.P. Nagare, V.S. Sneha, C. Sidhanth, S. Bindhya, P. Manasa and T.S. Ganesan

      Version of Record online: 14 MAY 2016 | DOI: 10.1002/ijc.30067

  7. Cancer Epidemiology

    1. Prediagnostic body size and breast cancer survival in the E3N cohort study

      Mathilde His, Guy Fagherazzi, Sylvie Mesrine, Marie-Christine Boutron-Ruault, Françoise Clavel-Chapelon and Laure Dossus

      Version of Record online: 14 MAY 2016 | DOI: 10.1002/ijc.30158

      What's new?

      If you're fat, you're less likely to survive breast cancer—but does it matter where that fat is on your body? Perhaps, according to a new report. These authors noted that previous work only considers the patient's BMI when studying prognosis. This study tested hip and waist circumference as well. They discovered that women with larger hip circumference had greater risk of death from all causes and from breast cancer, and of second invasive cancer than had women with smaller hips. No association was found with waist circumference or BMI, suggesting there's more to the story than BMI when it comes to cancer survival.

  8. Tumor Immunology and Microenvironment

    1. Confocal fluorescence microscopy to evaluate changes in adipocytes in the tumor microenvironment associated with invasive ductal carcinoma and ductal carcinoma in situ

      Jessica L. Dobbs, Dongsuk Shin, Savitri Krishnamurthy, Henry Kuerer, Wei Yang and Rebecca Richards-Kortum

      Version of Record online: 14 MAY 2016 | DOI: 10.1002/ijc.30160

      What's new?

      Adipose tissue assists breast carcinoma cells with invasion and metastasis through endocrine, inflammatory and angiogenic factors. “Activated” adipocytes adjacent to carcinoma are known to undergo extensive phenotypic changes including size reduction, although this phenomenon has yet to be quantitatively evaluated. The authors developed a computerized algorithm to identify and quantitatively characterize adipocytes at sites adjacent to and far from lesion margins in neoplastic and non-neoplastic tissue in confocal fluorescence microscopy images of fresh, unfixed breast tissue. The findings support further use of confocal microscopy to explore whether features of adjacent adipocytes can predict the invasive potential of early breast cancers.

  9. Cancer Therapy and Prevention

    1. Tobacco carcinogen induces both lung cancer and non-alcoholic steatohepatitis and hepatocellular carcinomas in ferrets which can be attenuated by lycopene supplementation

      Koichi Aizawa, Chun Liu, Sanyuan Tang, Sudipta Veeramachaneni, Kang-Quan Hu, Donald E. Smith and Xiang-Dong Wang

      Version of Record online: 14 MAY 2016 | DOI: 10.1002/ijc.30161

      What's new?

      Among the potent carcinogens in cigarette smoke is the nitrosamine 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone, or NNK. In rats, NNK induces pulmonary carcinogenesis and at high doses causes liver disease and hepatocellular carcinoma (HCC). Its effects in nonrodent animals are less clear. Using ferrets as a model, the authors of this study show that NNK exposure is associated with increased incidence of lung cancer, steatohepatitis, and HCC. NNK-induced pathological lesions in the lungs and livers of ferrets, however, were effectively attenuated with dietary lycopene supplementation. Lycopene may protect against NNK-induced lung and liver tumorigenesis by preventing the expression of key signaling proteins.

  10. Cancer Epidemiology

    1. Relationship of prediagnostic body mass index with survival after colorectal cancer: Stage-specific associations

      Jonathan M. Kocarnik, Andrew T. Chan, Martha L. Slattery, John D. Potter, Jeffrey Meyerhardt, Amanda Phipps, Hongmei Nan, Tabitha Harrison, Thomas E. Rohan, Lihong Qi, Lifang Hou, Bette Caan, Candyce H. Kroenke, Howard Strickler, Richard B. Hayes, Robert E. Schoen, Dawn Q. Chong, Emily White, Sonja I. Berndt, Ulrike Peters and Polly A. Newcomb

      Version of Record online: 14 MAY 2016 | DOI: 10.1002/ijc.30163

      What's new?

      Being overweight increases a person's risk of developing colorectal cancer, but does it also influence the likelihood of surviving it? These authors investigated. Drawing on data from six prospective cohort studies, they analyzed the relationship between body mass index before diagnosis and odds of survival. Because survival depends greatly on how advanced the cancer is when it's discovered, they controlled for stage at diagnosis. Interestingly, the effect of weight differed depending on disease stage. Among those with Stage I disease, being overweight appeared to increase mortality, but for those with Stage II–IV disease, higher BMI meant better survival.

  11. Tumor Immunology and Microenvironment

    1. B cells promote tumor progression in a mouse model of HPV-mediated cervical cancer

      Alexandre Tang, Gilles Dadaglio, Marine Oberkampf, Selene Di Carlo, Lucie Peduto, Daphné Laubreton, Belinda Desrues, Cheng-Ming Sun, Xavier Montagutelli and Claude Leclerc

      Version of Record online: 14 MAY 2016 | DOI: 10.1002/ijc.30169

      What's new?

      Subsets of regulatory T-cells and myeloid-derived suppressor cells serve influential roles in tumor-mediated immunosuppression and are of special interest in the development of novel antitumor immunotherapies. By comparison, little is known about the role of B cells in tumor immunity. Here, B cells overexpressing PD-L1, CD39 and Ly6A/E were found to promote tumor growth in an E6/E7-expressing TC-1 mouse model of cervical cancer. The B cells operated in an IL-10-independent manner. In μMT mice, the absence of B cells was associated with efficient antitumor T-cell responses. The findings suggest that in the tumor microenvironment, B-cell responses hamper antitumor immunity.

  12. Cancer Epidemiology

    1. Pancreatic cancer: Wait times from presentation to treatment and survival in a population-based study

      Valérie Jooste, Olivier Dejardin, Véronique Bouvier, Patrick Arveux, Marc Maynadie, Guy Launoy and Anne-Marie Bouvier

      Version of Record online: 14 MAY 2016 | DOI: 10.1002/ijc.30166

      What's new?

      Survival rates for pancreatic cancer remain exceedingly low. But while the disease often is not detected until advanced stages, whether delays in seeking physician care and in receiving treatment contribute to poor survival is unclear. In this population-based study in France, the presence of jaundice and metastatic dissemination were the two most relevant factors related to the timeliness of care, causing patients to consult a physician and being associated with short treatment delays. Nonetheless, timeliness of care had no impact on survival. The findings suggest that the advance of novel therapeutics will be key to improving pancreatic cancer survival.

    2. Inverse associations of dietary fiber and menopausal hormone therapy with colorectal cancer risk in the Multiethnic Cohort Study

      Song-Yi Park, Lynne R. Wilkens, Laurence N. Kolonel, Brian E. Henderson and Loïc Le Marchand

      Version of Record online: 14 MAY 2016 | DOI: 10.1002/ijc.30172

      What's new?

      In a large multiethnic cohort with a mean follow-up of 16 years, the authors found an inverse association of dietary fiber with colorectal cancer both in men and women. Postmenopausal women who had ever used menopausal hormone therapy (MHT) were at lower risk of colorectal cancer. Dietary fiber intake was associated with a lower risk in MHT-never users, but did not appear to further decrease the risk of MHT-ever users. No differences emerged across the five ethnic/racial groups included. These findings update an earlier report from the Multiethnic Cohort Study that found an inverse association for fiber only in men.

  13. Infectious Causes of Cancer

    1. Variant-specific persistence of infections with human papillomavirus Types 31, 33, 45, 56 and 58 and risk of cervical intraepithelial neoplasia

      Long Fu Xi, Mark Schiffman, Laura A. Koutsky, James P. Hughes, Ayaka Hulbert, Zhenping Shen, Denise A. Galloway and Nancy B. Kiviat

      Version of Record online: 14 MAY 2016 | DOI: 10.1002/ijc.30164

      What's new?

      Human papillomavirus (HPV) types 16 and 18 are among the most well-studied oncogenic HPVs. Certain lineages of other high-risk (HR) HPV types, however, are associated with an increased risk of cervical precancer, though little is known about their involvement in cervical disease. The present study examined the impact of persistent infection with HR-HPV 31, 33, 45, 56 or 58 on risk of precancerous cervical intraepithelial neoplasia Grades 2–3 (CIN2/3). The findings suggest that prolonged persistence of infection with non-HR variants does not mediate CIN2/3 risk. Rather, oncogenic heterogeneity of HR-HPV variants appears to be a more important factor.

  14. Cancer Epidemiology

    1. Invitation to cervical cancer screening does increase participation in Germany: Results from the MARZY study

      Kathrin Radde, Andrea Gottschalk, Ulrike Bussas, Stefanie Schülein, Dirk Schriefer, Ulrike Seifert, Anne Neumann, Melanie Kaiser, Maria Blettner and Stefanie J. Klug

      Version of Record online: 13 MAY 2016 | DOI: 10.1002/ijc.30146

      What's new?

      The success of organized cervical cancer screening (CCS) programs depends on the regular participation of eligible women. In Germany, however, where an organized screening program is under development, CCS participation rates vary, and how best to improve them in the coming years remains unclear. This study of women in Mainz and rural Mainz-Bingen shows that three-year CCS participation rates increase significantly when women receive personalized letters inviting them to undergo CCS. The invitation letter was especially effective for groups at high risk of nonparticipation in CCS, including women with lower education, migrant women, and older women.

  15. Tumor Immunology and Microenvironment

    1. Body mass index and risk of colorectal cancer according to tumor lymphocytic infiltrate

      Akiko Hanyuda, Shuji Ogino, Zhi Rong Qian, Reiko Nishihara, Mingyang Song, Kosuke Mima, Kentaro Inamura, Yohei Masugi, Kana Wu, Jeffrey A. Meyerhardt, Andrew T. Chan, Charles S. Fuchs, Edward L. Giovannucci and Yin Cao

      Version of Record online: 10 MAY 2016 | DOI: 10.1002/ijc.30122

      What's new?

      A vigorous immune response does not particularly hinder obesity-related cancer, according to new results. Being fat increases risk of colorectal cancer and a vigorous T-cell response can improve colorectal cancer prognosis. These authors suspected that immune cells around the tumor may suppress the oncogenic pathway induced by excess fat. Using data from the Nurses' Health Study and the Health Professionals Follow-up Study, they investigated whether the impact of BMI varied depending on the degree of lymphocytic infiltration. BMI association with colorectal cancer, they determined, did not vary with lymphocytic reaction or the density of T-cells infiltrating the tumor tissue.

  16. Cancer Epidemiology

    1. Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147

      Amanda I. Phipps, Qian Shi, Paul J. Limburg, Garth D. Nelson, Daniel J. Sargent, Frank A. Sinicrope, Emily Chan, Sharlene Gill, Richard M. Goldberg, Morton Kahlenberg, Suresh Nair, Anthony F. Shields, Polly A. Newcomb, Steven R. Alberts and for the Alliance for Clinical Trials in Oncology

      Version of Record online: 9 MAY 2016 | DOI: 10.1002/ijc.30135

      What's New?

      Drinking red wine may boost the odds of surviving colon cancer, according to a new analysis. In this paper, the authors investigated how alcohol consumption affects colorectal cancer outcomes. Previous work showed that moderate to heavy drinking put an individual at increased risk; this study went further, analyzing the effect of different drinks separately. While they found no association between alcohol consumption and outcomes overall, when they looked only at red wine, they found that people who drank between 1–30 glasses of red wine per month had better outcomes than those who did not drink wine.

  17. Molecular Cancer Biology

    1. Subtype-specific micro-RNA expression signatures in breast cancer progression

      Vilde D. Haakensen, Vegard Nygaard, Liliana Greger, Miriam R. Aure, Bastian Fromm, Ida R.K. Bukholm, Torben Lüders, Suet-Feung Chin, Anna Git, Carlos Caldas, Vessela N. Kristensen, Alvis Brazma, Anne-Lise Børresen-Dale, Eivind Hovig and Åslaug Helland

      Version of Record online: 9 MAY 2016 | DOI: 10.1002/ijc.30142

      What's new?

      Current debate about the overtreatment of noninvasive and indolent breast carcinomas is being addressed through multiple streams of research. Key among them is the identification of diagnostic measures of malignant potential, which could help reduce overtreatment. Here, analyses of data from two different studies on ductal carcinoma in situ (DCIS) and invasive breast carcinoma revealed subtype-specific microRNA signatures. The miRNA profiles were associated with transitions from normal tissue to DCIS and from DCIS to specific subtypes of invasive carcinoma. The miRNA signatures may be capable of predicting malignant potential in a clinical setting.

  18. Cancer Epidemiology

    1. Risk factors for metachronous colorectal cancer following a primary colorectal cancer: A prospective cohort study

      Harindra Jayasekara, Jeanette C. Reece, Daniel D. Buchanan, Christophe Rosty, S. Ghazaleh Dashti, Driss Ait Ouakrim, Ingrid M. Winship, Finlay A. Macrae, Alex Boussioutas, Graham G. Giles, Dennis J. Ahnen, Jan Lowery, Graham Casey, Robert W. Haile, Steven Gallinger, Loic Le Marchand, Polly A. Newcomb, Noralane M. Lindor, John L. Hopper, Susan Parry, Mark A. Jenkins and Aung Ko Win

      Version of Record online: 9 MAY 2016 | DOI: 10.1002/ijc.30153

      What's new?

      Individuals diagnosed with a colorectal cancer (CRC) are at increased risk of developing a metachronous CRC (a new primary CRC) in the remaining part of the large bowel later in life. Routine stratification of individuals based on their risk for metachronous CRC would allow prevention by surveillance colonoscopy to become cost-effective. In this prospective cohort study, location of the initial CRC in the proximal colon and presence of a synchronous CRC were associated with an increased risk of metachronous CRC, highlighting their importance when deciding on the intensity of surveillance colonoscopy. There was no evidence for associations between lifestyle and female reproductive factors and metachronous CRC risk.

  19. Cancer Genetics and Epigenetics

    1. Host genetic influence on papillomavirus-induced tumors in the horse

      Elizabeth A. Staiger, Chia T. Tseng, Donald Miller, Jennifer M. Cassano, Lubna Nasir, Dorian Garrick, Samantha A. Brooks and Douglas F. Antczak

      Version of Record online: 6 MAY 2016 | DOI: 10.1002/ijc.30120

      What's new?

      The most commonly occurring tumors in horses are equine sarcoids, skin growths that emerge following infection with bovine papillomaviruses type 1 or type 2 (BPV1, BPV2). Sarcoid incidence varies among horse breeds, however, suggesting a genetic basis. Here, two genomic regions, including an intron in DQA1 in the major histocompatibility complex (MHC) class II region on equine chromosome (ECA) 20 and a region containing four candidate genes on ECA 22, were found to influence papillomavirus-induced tumor development in the horse. MHC is similarly linked to virus-associated cancers in humans. Additional genomic investigation could fuel advances in equine sarcoid prevention and treatment.

  20. Tumor Immunology and Microenvironment

    1. Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer

      Jonna Berntsson, Björn Nodin, Jakob Eberhard, Patrick Micke and Karin Jirström

      Version of Record online: 6 MAY 2016 | DOI: 10.1002/ijc.30138

      What's new?

      When the immune system fights cancer, it doesn't just send T-cells – B cells join the effort as well. This study is the first to explore the correlation between certain B-cell markers and colorectal cancer outcomes. They suspected, based on prior findings, that high infiltration of B cells would signify a better colorectal cancer prognosis, and they showed that is indeed the case. Cells carrying the markers CD20, CD138, and IGKC have been shown in previous studies to improve outcomes in other cancers; these authors similarly observed that in colorectal cancer, expression of these cells indicates better overall survival.

  21. Cancer Epidemiology

    1. You have full text access to this OnlineOpen article
      Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix?

      Alejandra Castanon, Rebecca Landy and Peter D. Sasieni

      Version of Record online: 6 MAY 2016 | DOI: 10.1002/ijc.30152

      What's new?

      Organised cervical cancer screening programs have helped reduce the incidence of squamous carcinoma of the cervix, however the incidence of adenocarcinoma is on the rise. In some countries, this has led to a shift in the distribution of morphological types. The present study shows that, while cytology screening is capable of detecting early-stage invasive adenocarcinoma and thereby prevents Stage 1B and worse adenocarcinomas, but it is substantially less good at detecting glandular than squamous precancerous lesions and therefore often fails to prevent stage 1A adenocarcinoma. The authors suggest that the effectiveness of cytology for cervical adenocarcinoma prevention may be strengthened when combined with other screening technologies.

  22. Molecular Cancer Biology

    1. A key role for galectin-1 in sprouting angiogenesis revealed by novel rationally designed antibodies

      Judy R. van Beijnum, Victor L. Thijssen, Tilman Läppchen, Tse J. Wong, Iris Verel, Maurits Engbersen, Iris A. Schulkens, Raffaella Rossin, Holger Grüll, Arjan W. Griffioen and Patrycja Nowak-Sliwinska

      Version of Record online: 5 MAY 2016 | DOI: 10.1002/ijc.30131

      What's New?

      Galectins are carbohydrate-binding proteins with an essential role in tumor angiogenesis and whose expression is associated with disease progression. Based on a rational approach, here the authors generated and characterized two novel mouse monoclonal antibodies that specifically react with galectin-1 in human, mouse and chicken. The antibodies are promising tools to study galectin-1 expression and function in a broad array of biological systems. In a potential diagnostic application, radiolabeled antibodies showed specific targeting of galectin-1 positive tumors. In a therapeutic setting, the antibodies inhibited sprouting angiogenesis in vitro and in vivo, underscoring the key function of galectin-1 in this process.

  23. Tumor Markers and Signatures

    1. BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial

      Philip C. Schouten, Oleg Gluz, Nadia Harbeck, Svjetlana Mohrmann, Raihana Diallo-Danebrock, Enrico Pelz, Janneke Kruizinga, Arno Velds, Marja Nieuwland, Ron M Kerkhoven, Cornelia Liedtke, Markus Frick, Ronald Kates, Sabine C. Linn, Ulrike Nitz and Frederik Marme

      Version of Record online: 5 MAY 2016 | DOI: 10.1002/ijc.30078

      What's New?

      BRCA1 is key to the repair of DNA double-strand breaks, such that its deficiency, as in BRCA1-deficient breast cancer, renders tumors susceptible to DNA damage induced by high-dose (HD) alkylating chemotherapy. For high-risk, stage III breast cancer (HRBC) patients, however, HD chemotherapy is controversial due to its treatment burden and no strong benefit in the general breast cancer population. This study shows that HRBC patients whose tumors present a BRCA1-like signature—a pattern of copy number aberrations characteristic of BRCA1 deficiency—experience greater improvements in survival after tandem HD chemotherapy versus conventional dose-dense chemotherapy. Non-BRCA1-like patients did not benefit to the same degree. The study validates and extends previous findings.

  24. Cancer Epidemiology

    1. The association of soy food consumption with the risk of subtype of breast cancers defined by hormone receptor and HER2 status

      Michelle L. Baglia, Wei Zheng, Honglan Li, Gong Yang, Jing Gao, Yu-Tang Gao and Xiao-Ou Shu

      Version of Record online: 5 MAY 2016 | DOI: 10.1002/ijc.30117

      What's New?

      Low rates of breast cancer among women in Asian countries and its rapid increase following emigration to Western cultures has led to dietary factors being postulated as important factors. While soy food intake has been associated with reduced breast cancer risk, epidemiological evidence for subgroups of breast cancer, particularly by menopausal and hormone receptor status, is less consistent. This large cohort study suggests that soy food intake is associated with both ER/PR-positive and negative breast cancer risk, with the association differing by menopausal status. No modification by HER2 status was observed. Soy food may thus influence breast cancer risk via multiple mechanisms.

  25. Molecular Cancer Biology

    1. A cellular model reflecting the phenotypic heterogeneity of mutant HRAS driven squamous cell carcinoma

      Neus Cantariño, M. Teresa Fernández-Figueras, Vanesa Valero, Eva Musulén, Roberto Malinverni, Isabel Granada, Stephen J. Goldie, Juan Martín-Caballero, Julien Douet, Sonia-Vanina Forcales and Marcus Buschbeck

      Version of Record online: 5 MAY 2016 | DOI: 10.1002/ijc.30139

      What's New?

      The histopathological heterogeneity encountered in non-melanoma skin tumours and even within the same tumour class such as squamous cell carcinoma (SCC) is still poorly understood. Here, the authors report the generation of a set of cell lines that reflect part of SCC heterogeneity and represent different stages of skin cancerogenesis. The model has the potential to be used as a unique tool for the study of genetic and non-genetic mechanisms underlying case-to-case heterogeneity. It also offers a linear model for the discovery of novel cancer driver genes and the development of drugs targeting Ras proteins or their downstream signaling components.

  26. Tumor Markers and Signatures

    1. Serum pepsinogen levels can quantify the risk of development of metachronous gastric cancer after endoscopic resection

      Mikitaka Iguchi, Jun Kato, Takeichi Yoshida, Yasuhide Yamamoto, Kenichiro Nakachi, Kazuhiro Fukatsu, Yoshiyuki Mori, Yoshimasa Maeda, Kosaku Moribata, Naoki Shingaki, Toru Niwa, Hisanobu Deguchi, Izumi Inoue, Takao Maekita, Hideyuki Tamai and Masao Ichinose

      Version of Record online: 5 MAY 2016 | DOI: 10.1002/ijc.30145

      What's New?

      Helicobacter pylori infection is a frequent cause of chronic gastritis, which in the presence of an aggressive inflammatory milieu progresses to gastric atrophy, intestinal metaplasia and cancer. For some patients, H. pylori eradication can reduce gastric cancer development, though whether this is true for metachronous gastric cancer (MGC) remains uncertain. In this study, H. pylori eradication was found to have no affect on MGC incidence following endoscopic resection, which inevitably leaves behind atrophied gastric mucosa, a possible source of cancer development. MGC development was predicted by serum pepsinogen I/II ratio, identified here as a marker of gastric atrophy.

  27. Cancer Epidemiology

    1. Causes and outcomes of emergency presentation of rectal cancer

      Harry Comber, Linda Sharp, Marianna de Camargo Cancela, Trutz Haase, Howard Johnson and Jonathan Pratschke

      Version of Record online: 5 MAY 2016 | DOI: 10.1002/ijc.30149

      What's New?

      Regardless of cancer stage, emergency admission for rectal cancer carries a higher death rate than planned admission. To understand what leads to emergency presentation, these authors devised a new statistical technique to distinguish direct and indirect effects of various factors, including possession of private insurance, age and marital status. The factors that contributed to emergency presentation are similar to those that cause a delay in diagnosis: age, poverty, marital status. Thus, they conclude, patient education and improved access to screening for patients on public insurance would reduce the number of emergency admissions.

    2. Stillbirth and neonatal death among female cancer survivors: A national cohort study

      Jianguang Ji, Jan Sundquist and Kristina Sundquist

      Version of Record online: 5 MAY 2016 | DOI: 10.1002/ijc.30156

      What's New?

      Increasing numbers of people are surviving cancer, and many of those survivors are young or of child-bearing age and want to have children. However, little is known about the consequences of cancer treatments, particularly radiotherapy or chemotherapy, on pregnancy outcomes. Here, the authors identify a window of time—within three years after maternal cancer diagnosis—when risk of stillbirth is increased for women who survived cancer and subsequently became pregnant. The risk of stillbirth dropped significantly for later, additional childbirths, indicating a weakening of adverse effects over time.

  28. Molecular Cancer Biology

    1. Development of ZMYM2-FGFR1 driven AML in human CD34+ cells in immunocompromised mice

      Mingqiang Ren, Haiyan Qin, Qing Wu, Natasha M. Savage, Tracy I. George and John K. Cowell

      Version of Record online: 4 MAY 2016 | DOI: 10.1002/ijc.30100

      What's new?

      Rearrangements involving FGFR1 kinase lead to the development of an atypical myeloproliferative disorder that frequently progresses to acute myelogenous leukemia (AML). Conventional therapeutic strategies are largely unsuccessful, and because of the rare nature of this syndrome, models that faithfully mimic the human disease are needed. This is the first report of a transplantable, humanized model of FGFR1-driven AML in immunocompromized mice. The disease is faithfully mimicked and molecular analysis shows genetic changes consistent with stem cell leukemias. The model provides a new tool to both better understand the molecular mechanisms underlying the primary human disease and develop novel therapeutic approaches.

  29. Cancer Therapy and Prevention

    1. You have full text access to this OnlineOpen article
      Use of thermo-coagulation as an alternative treatment modality in a ‘screen-and-treat’ programme of cervical screening in rural Malawi

      Christine Campbell, Savel Kafwafwa, Hilary Brown, Graeme Walker, Belito Madetsa, Miriam Deeny, Beatrice Kabota, David Morton, Reynier Ter Haar, Liz Grant and Heather A. Cubie

      Version of Record online: 4 MAY 2016 | DOI: 10.1002/ijc.30101

      What's new?

      Malawi has the highest incidence rates for cervical cancer worldwide, and a “screen-and-treat” program is in place to identify and treat precancerous lesions. Conventional cryotherapy is challenging as gas supply is inconsistent, cylinders are difficult to transport and running costs are high. Here, the authors introduce thermo-coagulation as a treatment alternative, which proved feasible and acceptable in this resource-poor setting and could increase the number of women receiving timely treatment for precancerous lesions in low- and middle-income countries.

  30. Cancer Genetics and Epigenetics

    1. Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis

      Rong Bu, Abdul K. Siraj, Khadija A.S. Al-Obaisi, Shaham Beg, Mohsen Al Hazmi, Dahish Ajarim, Asma Tulbah, Fouad Al-Dayel and Khawla S. Al-Kuraya

      Version of Record online: 3 MAY 2016 | DOI: 10.1002/ijc.30143

      What's new?

      Genetic testing for BRCA mutations reveals the ethnic diversity of prevalence and spectrum of BRCA1/BRCA2 mutations in breast cancer. Compared with other populations, however, little is known about ethnic differences in breast cancer genomics in populations in the Middle East region. Here, BRCA mutation screening was carried out in 818 Middle Eastern breast cancer patients. The authors identify two putative founder mutations—together accounting for more than 46% of BRCA cases—and a particular spectrum of deleterious BRCA mutations, which may be unique to the population. The findings could impact genetic counseling in Middle Eastern populations.

  31. Mini Reviews

    1. You have free access to this content
      Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy

      Keiran S.M. Smalley, Inna V. Fedorenko, Rajappa S. Kenchappa, Solmaz Sahebjam and Peter A. Forsyth

      Version of Record online: 30 APR 2016 | DOI: 10.1002/ijc.30147

  32. Cancer Epidemiology

    1. Irregular menses predicts ovarian cancer: Prospective evidence from the Child Health and Development Studies

      Piera M. Cirillo, Erica T. Wang, Marcelle I. Cedars, Lee-may Chen and Barbara A. Cohn

      Version of Record online: 29 APR 2016 | DOI: 10.1002/ijc.30144

      What's new?

      The lack of specific early symptoms in ovarian cancer, aggressiveness of some of the histopathologic subtypes and need for more effective screening and treatment strategies are evidenced by a dismal 5-year survival rate for all stages. While several studies have reported ovarian cancer associations with menstrual cycle variability, the findings are inconsistent. This study provides the first prospective evidence that women with irregular menstrual cycles are at higher risk of ovarian cancer. Discovering high-risk phenotypes such as irregular menstruation creates opportunities to find novel early biomarkers, refine clinical screening protocols and potentially develop new risk reduction strategies for ovarian cancer.

  33. Infectious Causes of Cancer

    1. Clonal deleted latent membrane protein 1 variants of Epstein-Barr virus are predominant in European extranodal NK/T lymphomas and disappear during successful treatment

      Mohamad Adnan Halabi, Arnaud Jaccard, Rémi Moulinas, Racha Bahri, Hazar Al Mouhammad, Nour Mammari, Jean Feuillard and Sylvie Ranger-Rogez

      Version of Record online: 29 APR 2016 | DOI: 10.1002/ijc.30128

      What's new?

      Extranodal natural killer/T-cell lymphoma (NK/TL) is a rare and highly aggressive cancer. Epstein-Barr virus (EBV) has been found in all cases of NK/TL studied so far. In this study, the authors found that the EBV LMP1 gene contains a small deletion in all biopsies from European patients. In patients who achieved complete remission, however, the wild-type form of LMP1 became more common during treatment. Monitoring EBV strains may thus provide a useful tool for assessing treatment efficacy in NK/TL.

  34. Letters to the Editor

  35. Tumor Markers and Signatures

    1. MRP1 expression in CTCs confers resistance to irinotecan-based chemotherapy in metastatic colorectal cancer

      Emne Ali Abdallah, Marcello Ferretti Fanelli, Virgílio Souza, e Silva, Marcelo Calil Machado Netto, José Luiz Gasparini Junior, Daniel Vilarim Araújo, Luciana Menezes Mendonça Ocea, Marcilei Eliza Cavicchioli Buim, Milena Shizue Tariki, Vanessa da Silva Alves, Victor Piana de Andrade, Aldo Lourenço Abbade Dettino, Celso Abdon Lopes de Mello and Ludmilla Thomé Domingos Chinen

      Version of Record online: 28 APR 2016 | DOI: 10.1002/ijc.30082

      What's new?

      Wouldn't it be nice to know right away when a patient's cancer becomes drug-resistant? New results suggest that a molecular marker, MRP1, on circulating tumor cells could provide just such a tip. These authors studied patients with metastatic colorectal cancer who were receiving irinotecan therapy. They tested the patients' circulating tumor cells for various marker proteins, and when the cells carried MRP1, irinotecan resistance was more likely.

  36. Cancer Therapy and Prevention

    1. Human papillomavirus mRNA and DNA testing in women with atypical squamous cells of undetermined significance: A prospective cohort study

      Louise T. Thomsen, Christian Dehlendorff, Jette Junge, Marianne Waldstrøm, Doris Schledermann, Kirsten Frederiksen and Susanne K. Kjaer

      Version of Record online: 26 APR 2016 | DOI: 10.1002/ijc.30104

      What's new?

      Testing for human papillomavirus (HPV) DNA in women with atypical squamous cells of undetermined significance (ASC-US) is widely implemented in cervical cancer screening, despite suboptimal specificity. An emerging alternative is HPV mRNA testing, though few prospective studies have compared HPV mRNA and DNA testing for ASC-US triage. Here, in a cohort of 13,729 women, a commercial mRNA test for five different HPV types was found to be more specific but far less sensitive for high-grade cervical intraepithelial neoplasia than widely used HPV DNA tests. The authors conclude that five-type HPV mRNA testing is not optimal for ASC-US triage.

  37. Cancer Epidemiology

    1. Is human herpesvirus 8 infection more common in men than in women? Systematic review and meta-analysis

      Lorin Begré, Eliane Rohner, Sam M. Mbulaiteye, Matthias Egger and Julia Bohlius

      Version of Record online: 26 APR 2016 | DOI: 10.1002/ijc.30129

      What's new?

      All forms of Kaposi sarcoma are more common in men than in women but the association of gender with human herpesvirus 8 (HHV8) status is less clear. In this meta-analysis of existing data, the authors found that men from sub-Saharan Africa, where HHV-8 is endemic, were more likely to be HHV-8 seropositive than women. This association was only found in sub-Saharan Africa and did not apply to boys in the same region, raising the question of sexual transmission and hormonal status as additional factors in Kaposi sarcoma development.

    2. CYP1A1, GSTM1 and GSTT1 genetic polymorphisms and gastric cancer risk among Japanese: A nested case–control study within a large-scale population-based prospective study

      Akihisa Hidaka, Shizuka Sasazuki, Keitaro Matsuo, Hidemi Ito, Hadrien Charvat, Norie Sawada, Taichi Shimazu, Taiki Yamaji, Motoki Iwasaki, Manami Inoue, Shoichiro Tsugane and for the JPHC Study Group

      Version of Record online: 26 APR 2016 | DOI: 10.1002/ijc.30130

      What's new?

      The study of association between CYP1A1, GSTM1 and GSTT1 genetic polymorphisms and gastric cancer risk was done in recent several meta-analyses. However, most individual studies are retrospective, and their sample sizes are small. Although neither gene–gene nor gene–environment interactions were significant, the CYP1A1 (rs4646422) polymorphism might be involved in gastric carcinogenesis among the Japanese population.

  38. Tumor Immunology and Microenvironment

    1. IL17 producing γδT cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients

      Rushikesh Sudam Patil, Sagar Umesh Shah, Shailesh Vinayak Shrikhande, Mahesh Goel, Rajesh Prabhakar Dikshit and Shubhada Vivek Chiplunkar

      Version of Record online: 26 APR 2016 | DOI: 10.1002/ijc.30134

      What's new?

      Human T cells expressing γδ-TCR exhibit potent anti-tumor activity and are potential candidates for cell-based therapies. Evidence however also exists of the ability of γδ-TCR cells to suppress anti-tumor responses, making deeper insight necessary for the successful clinical application of γδT cell-based immunotherapies. This study identified IL17-producing γδT cells (Tγδ17) as a pro-tumorigenic subtype of γδT cells associated with poor survival in gallbladder cancer (GBC) patients. Tγδ17 cells infiltrate the tumor bed via CXCL9-CXCR3 axis and IL17 induces pro-angiogenic factors in GBC cells. Tγδ17 may be considered as a predictive biomarker in GBC, opening up new avenues for targeted therapies.

  39. Cancer Therapy and Prevention

    1. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer

      Kohei Shigeta, Hirotoshi Hasegawa, Koji Okabayashi, Masashi Tsuruta, Yoshiyuki Ishii, Takashi Endo, Hiroki Ochiai, Takayuki Kondo and Yuko Kitagawa

      Version of Record online: 23 APR 2016 | DOI: 10.1002/ijc.30127

      What's new?

      This study was the first to evaluate the safety and efficacy of a new combination therapy called TEGAFIRI. This therapy combines one of the most common chemotherapy agents in Europe and Japan, the oral fluoropyramidine UFT/LV, and combines it with irinotecan. They compared TEGAFIRI with the combination of 5-FU/LV and irinotecan, called FOLFIRI, in patients with metastatic colorectal cancer who had not been treated before. They found no difference in progression-free survival between patients treated with either therapy. Further, they showed that the side effects of TEGAFIRI were no worse than those from FOLFIRI.

  40. Molecular Cancer Biology

    1. h-Prune is associated with poor prognosis and epithelial–mesenchymal transition in patients with colorectal liver metastases

      Masakazu Hashimoto, Tsuyoshi Kobayashi, Hirotaka Tashiro, Koji Arihiro, Akira Kikuchi and Hideki Ohdan

      Version of Record online: 21 APR 2016 | DOI: 10.1002/ijc.30118

      What's new?

      Once colorectal cancer spreads to the liver, it becomes much more deadly, despite advances in treatment. Could there be a way to predict survival for these cancers? These authors investigated the protein h-prune, which is associated with tumor aggressiveness. When they analyzed specimens of colorectal liver tumor metastases, they found h-prune in 28% of cases, and these had poorer survival than patients whose tumors lacked h-prune. In cell culture, h-prune promoted cell motility and boosted production of proteins involved in metastasis, while in mice it increased tumor invasiveness. Thus, h-prune could be a valuable prognostic tool or therapeutic target.

  41. Tumor Markers and Signatures

    1. Elevated expression of the centromere protein-A(CENP-A)-encoding gene as a prognostic and predictive biomarker in human cancers

      Xia Sun, Pier-Luc Clermont, Wenlin Jiao, Cheryl D. Helgason, Peter W. Gout, Yuzhuo Wang and Sifeng Qu

      Version of Record online: 21 APR 2016 | DOI: 10.1002/ijc.30133

      What's new?

      Elevated expression of Centromere protein-A (CENP-A), a histone-H3 variant with a regulatory role in cell division, has been associated with cancer progression. Using publicly available databases, this study demonstrates that elevated CENP-A expression is coupled to malignant progression of numerous types of cancer. In particular, it can be used as a critically needed biomarker for (i) poor patient prognosis and (ii) predicting the response of breast cancer patients to taxane-based chemotherapy.

  42. Molecular Cancer Biology

    1. RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy

      Hiroki Osumi, Eiji Shinozaki, Mitsukuni Suenaga, Satoshi Matsusaka, Tsuyoshi Konishi, Takashi Akiyoshi, Yoshiya Fujimoto, Satoshi Nagayama, Yosuke Fukunaga, Masashi Ueno, Yoshihiro Mise, Takeaki Ishizawa, Yosuke Inoue, Yu Takahashi, Akio Saiura, Hirohumi Uehara, Mingyon Mun, Sakae Okumura, Nobuyuki Mizunuma, Yoshio Miki and Toshiharu Yamaguchi

      Version of Record online: 19 APR 2016 | DOI: 10.1002/ijc.30106

      What's new?

      Previous studies have demonstrated a relationship between clinical outcomes following curative resection for colorectal cancer and gene mutations of the EGFR pathway. However, so far no studies have focused on metastatic colorectal cancer (mCRC) patients with metastasectomy. The aim of this study was thus to evaluate the relationship between gene mutations of the EGFR pathway and clinical outcomes following metastasectomy in mCRC patients. The results show that RAS mutation predicts shorter overall survival after metastasectomy in patients with metastatic colorectal cancer. No association between recurrence free survival and gene mutation of the EGFR pathway was observed.

  43. Cancer Epidemiology

    1. Changes over time in the impact of gene-expression profiles on the administration of adjuvant chemotherapy in estrogen receptor positive early stage breast cancer patients: A nationwide study

      A. Kuijer, C.A. Drukker, S.G. Elias, C.H. Smorenburg, E.J. Th. Rutgers, S. Siesling and Th. van Dalen

      Version of Record online: 19 APR 2016 | DOI: 10.1002/ijc.30132

      What's new?

      In the Netherlands, gene-expression profiling was introduced in 2004 to help guide decisions about the administration of adjuvant chemotherapy in patients with early-stage estrogen receptor-positive breast cancer. Since then, indications for adjuvant chemotherapy have broadened beyond the results of gene-expression profiling to include the majority of early-stage breast cancer patients. This study shows that since 2004, the number of Dutch patients eligible for adjuvant chemotherapy has increased by 13 percent. Despite broader clinical guidelines, however, over time gene-expression profile use appears to be associated with more consistent use of adjuvant chemotherapy and high adherence rates.

    2. Patients' perceptions of mortality risk for localized prostate cancer vary markedly depending on their treatment strategy

      Friederike Kendel, Lukas Helbig, Konrad Neumann, Jan Herden, Carsten Stephan, Mark Schrader and Wolfgang Gaissmaier

      Version of Record online: 19 APR 2016 | DOI: 10.1002/ijc.30123

      What's new?

      Patients with localized prostate cancer typically must choose between invasive treatments, like radical prostatectomy (RP), and less-invasive strategies, including active surveillance (AS). It is probable that the strategy chosen is the one patients think is most likely to minimize risk of death. However, communicating risk probabilities to patients is a great challenge. Here, men on AS and after RP were asked to rate the risk of dying from localized prostate cancer. The results show that all men, irrespective of the chosen treatment, overestimated prostate cancer mortality risk by 20–50 absolute percentage points. The findings indicate a need for better patient education.

    3. Risk of solid tumors and hematological malignancy in persons with Turner and Klinefelter syndromes: A national cohort study

      Jianguang Ji, Bengt Zöller, Jan Sundquist and Kristina Sundquist

      Version of Record online: 19 APR 2016 | DOI: 10.1002/ijc.30126

      What's new?

      Several microRNAs located on the human X chromosome have roles in cancer, suggesting that abnormalities in X chromosome number or structure can affect cancer risk. This longitudinal study in Sweden explored the risk of solid and hematological malignancy in women with Turner syndrome (X chromosome monosomy) and men with Klinefelter syndrome (two or more X chromosomes). Solid tumor incidence was increased in Turner syndrome patients but decreased in patients with Klinefelter syndrome. Though the mechanism remains unknown, the posited role of X chromosome disorders in solid tumor etiology may be associated with the loss or dysfunction of immune-related genes.

  44. Cancer Therapy and Prevention

    1. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors

      Caterina Vivaldi, Chiara Caparello, Gianna Musettini, Giulia Pasquini, Silvia Catanese, Lorenzo Fornaro, Monica Lencioni, Alfredo Falcone and Enrico Vasile

      Version of Record online: 18 APR 2016 | DOI: 10.1002/ijc.30125

      What's new?

      Standard first-line therapy for advanced pancreatic cancer centers on FOLFIRINOX, a combination regimen using 5-fluorouracil, irinotecan, oxaliplatin, and gemcitabine plus nabpaclitaxel. The regimen's increased adverse effects, however, warrant investigation of alternative drug combinations. Here, modified Gruppo Oncologico Nord Ovest FOLFOXIRI (5-fluorouracil, leucovorin, irinotecan and oxaliplatin) was found to produce survival results similar to those of FOLFIRINOX in patients with pancreatic cancer. The modified FOLFOXIRI regimen also compared favorably with FOLFIRINOX in terms of gastrointestinal adverse events. Prognostic factors were identified, enabling FOLFOXIRI-treated patients to be stratified into subgroups with different survival outcomes.

  45. Mini Reviews

  46. Cancer Therapy and Prevention

    1. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein

      Manal Amoury, Radoslav Mladenov, Thomas Nachreiner, Anh-Tuan Pham, Dmitrij Hristodorov, Stefano Di Fiore, Wijnand Helfrich, Alessa Pardo, Georg Fey, Michael Schwenkert, Theophilus Thepen, Fabian Kiessling, Ahmad F. Hussain, Rainer Fischer, Katharina Kolberg and Stefan Barth

      Version of Record online: 15 APR 2016 | DOI: 10.1002/ijc.30119

      What's New?

      New therapies for triple-negative breast cancer (TNBC) are urgently needed. It would be ideal if such a therapy could specifically target TNBC cells. In this study, the authors engineered a fusion protein composed of an antibody fragment that binds to TNBC cells, plus a protein called MAP tau that kills these proliferating cells. This cytolytic fusion protein caused tumor regression in mice carrying human TNBC tumors. These results indicate that this novel molecule may be a promising immunotherapy for TNBC.

  47. Tumor Immunology and Microenvironment

    1. Induction of antigen-specific TH9 immunity accompanied by mast cell activation blocks tumor cell engraftment

      Aws Abdul-Wahid, Marzena Cydzik, Aaron Prodeus, Mays Alwash, Mile Stanojcic, Megan Thompson, Eric H.-B. Huang, John E. Shively, Scott D. Gray-Owen and Jean Gariépy

      Version of Record online: 15 APR 2016 | DOI: 10.1002/ijc.30121

      What's new?

      The vast majority of cancer deaths are the result of metastasis, yet the integration of circulating tumor cells at sites distant from the tumor of origin remains largely unexplored from the view of therapeutics. A vaccine capable of neutralizing circulating tumor cells, however, could be key to preventing or delaying metastasis, according to this study. A carcinoembryonic antigen (CEA)-based vaccine with a focused response against the IgV-like N domain successfully generated a CEA-specific TH9 response that blocked the establishment of metastatic tumor nodules in mice. This alternate tumor-eradication mechanism could aid the development of metastasis-preventing immunotherapies.

  48. Mini Reviews

    1. ALDH1A3, a metabolic target for cancer diagnosis and therapy

      Jiang-Jie Duan, Jiao Cai, Yu-Feng Guo, Xiu-Wu Bian and Shi-Cang Yu

      Version of Record online: 4 APR 2016 | DOI: 10.1002/ijc.30091


  1. 1 - 57